Sanofi

Sanofi

Global pharma company; vaccines and R&D

Accelerator Staff Software Engineer

Full-TimePosted on 7/2/2026Deadline 8/8/26
€76k - €101.3k/yr
Senior
Bachelor's
Marcy-l'Étoile, France
Hybrid

Hybrid role: 60% office-based in Lyon, 40% remote.

About the job

Requirements
  • Significant experience in software engineering (or equivalent knowledge). If you feel qualified, apply regardless of years of experience!
  • Experience in an innovative, fast-paced environment
  • Proven track record of leading technical initiatives and mentoring senior engineers
  • Soft skills: Strong problem-solving and critical thinking skills; Service-oriented, flexible, and a team player who takes initiative; Excellent written and verbal communication in English; Growth mindset with enthusiasm for learning new technologies and approaches; Innovation-focused with a willingness to experiment and introduce improved ways of working; Collaborative leadership that fosters inclusivity and innovation
  • Bachelor’s degree in Computer Science, Engineering, or equivalent experience is a plus
  • Your background mentions experience in an innovative, fast-paced environment (repeat included)
  • Experience in leading technical initiatives and mentoring senior engineers (repeat)
  • Technical requirements (as separate)
Responsibilities
  • Serves as a technical leader and role model within the engineering organization
  • Shapes technical direction for complex systems and ensures scalable, maintainable architectures
  • Leads initiatives that impact multiple teams and domains across the M&S Accelerator
  • Identifies leverage points to unlock exponential productivity gains for the organization
  • Owns technical decisions for critical projects, ensuring delivery on deadlines and quality standards
  • Anticipates challenges and proactively resolves bottlenecks
  • Works across teams to align execution with organizational strategy and priorities
  • Balances pragmatism with technical excellence to accelerate delivery
  • Ensure data-driven decision-taking
  • Designs and builds robust software solutions for research workflows and data analysis
  • Establishes and enforces technical standards, patterns, and best practices across teams
  • Develops deep expertise in cloud-native systems, microservices, APIs, and security
  • Champions CI/CD, DevOps principles, and cloud infrastructure as code
  • Mentors senior engineers, enabling them to take on greater ownership and leadership
  • Promotes a culture of engineering excellence, knowledge sharing, and innovation
  • Encourages open dialogue where team members feel safe to share ideas and learn from mistakes
  • Contributes to talent growth by participating in hiring and career development
  • Acts as a bridge across engineering, product, and scientific teams to ensure alignment and results
  • Advocates for best engineering practices and drives adoption across domains
  • Collaborates with peers and leaders to shape technical strategy for the Accelerator
  • Represents engineering in discussions with external partners and vendors

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi completed Vicebio on December 4, 2025, adding RSV-HMPV vaccine technology.
  • Sanofi completed Dynavax on February 10, 2026, expanding hepatitis B and shingles assets.
  • FDA approved wearable Sarclisa on July 2026, improving multiple myeloma convenience.

What critics are saying

  • Dupixent loses patent exclusivity in 2031, exposing Sanofi’s cash engine.
  • EU regulators opened a June 26, 2026 antitrust probe over Efluelda marketing.
  • Sanofi sued Pfizer and Moderna on July 15, 2026 over COVID-shot patents.

What makes Sanofi unique

  • Dupixent and partner Regeneron still anchor Sanofi’s immunology franchise in 2026.
  • Vicebio’s Molecular Clamp and Dynavax deepen Sanofi’s respiratory and adult vaccine platform.
  • Frankfurt insulin manufacturing, backed by Germany’s 2026 subsidy, protects European supply security.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Electra Therapeutics
Sep 11th, 2026
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced an oversubscribed $183 million Series C financing. The round was co-led by Nextech and EQT Life Sciences...

INACTIVE